Gene delivery by Adeno-Associated Virus (AAV) vectors is a popular technique. However, it has drawbacks, including immunological reactions. Optimizing its payload capacity, delivery efficiency, and insertional mutagenesis risk are obstacles that must be overcome. To overcome these problems, experts are creating new AAV serotypes with improved tissue specificity and efficiency, shortening production procedures to increase yield, and using genome-editing techniques to reduce insertional risks.